Trevi Therapeutics, Inc.

US$14.33As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:TRVIHealthcare
Country USA
PE (Fwd) •••
TSR 7Y CAGR 4.97%
Div yield —
ROE (19.66%)
Biotechnology
Beta (5Y) 1.12
PE TTM —
TSR TTM 22.90%
Mkt cap US$2.042B
ROIC (14.28%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$18
28.42%
(53.86%)
Hold 10|0|12|0|5
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.23
0.24
0.26
0.29
5.58%
8.42%
6.72%
20.44%
Revenue$M
166.9
171.2
169.0
172.4
18.22%
14.71%
7.34%
5.53%
Peers (US$2.042B)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
3.760
0.049
0.038
EBIT/Intx
0.181
0.071
0.087
Own earn%
(24.54)
(205.28)
(195.38)
Sh yield%
34.64
26.51
24.66
Owners
Insiders/Inst%
5.73
76.36
Short interest%
2.39
SBC / revenue%
5.68
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
5
Op margin range%
11–21
$1 testx
−0.2
Incr. ROIC%
30